Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral main...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Richard A., Fisher, David J., Graham, Janet, Seligmann, Jenny F., Seymour, Matthew, Kaplan, Richard, Yates, Emma, Parmar, Mahesh, Richman, Susan D., Quirke, Philip, Butler, Rachel, Brown, Ewan, Collinson, Fiona, Falk, Stephen, Wasan, Harpreet, Shiu, Kai-Keen, Middleton, Gary, Samuel, Leslie, Wilson, Richard H., Brown, Louise C., Maughan, Timothy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601309/
https://www.ncbi.nlm.nih.gov/pubmed/34516759
http://dx.doi.org/10.1200/JCO.21.01436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601309/
https://www.ncbi.nlm.nih.gov/pubmed/34516759
http://dx.doi.org/10.1200/JCO.21.01436

Ejemplares similares